Cerbomed GmbH, an innovative medical device company concentrated on the development of new technologies for neuromodulation, has selected the CRO clinicalprojects international GmbH (CPI) to drive its multi-center European trial to investigate the use of transcutaneous Vagus Nerve Stimulation (t-VNS®) for the treatment of drug-resistant epilepsy.
CPI began assisting cerbomed with this international study in late November 2011. "We awarded this clinical trial to CPI primarily because of their expertise in the area of neuromodulation, as well as the very positive feedback we received from CPI's reference clients" commented Prof. Dr. med. Jens Ellrich, Chief Medical Officer at cerbomed. "We believe that CPI is a dynamic and proactive CRO, and because they are a relatively small organization, we felt that they best understood the needs of a small and innovative medical device company".
"We are delighted that cerbomed has entrusted us with their trial and look forward to a successful collaboration with the cerbomed team" said Jörg Breitkopf, Managing Director of CPI. "cerbomed's decision to award CPI this important project is a further confirmation of our growing reputation among medical device companies as a highly regarded international CRO for clinical trial support."
About cerbomed GmbH
cerbomed GmbH is currently working on transcutaneous Vagus Nerve Stimulation (t-VNS®), an emerging therapy option for patients with difficult-to-treat neurological and psychiatric illnesses. Its transcutaneous vagus nerve stimulator NEMOS® received the European clearance (CE mark) in 2011. The start of clinical trials to investigate the effectiveness of t-VNS® for the treatment of patients with drug-resistant epilepsy and chronic migraine are planned for early 2012.
CPI began assisting cerbomed with this international study in late November 2011. "We awarded this clinical trial to CPI primarily because of their expertise in the area of neuromodulation, as well as the very positive feedback we received from CPI's reference clients" commented Prof. Dr. med. Jens Ellrich, Chief Medical Officer at cerbomed. "We believe that CPI is a dynamic and proactive CRO, and because they are a relatively small organization, we felt that they best understood the needs of a small and innovative medical device company".
"We are delighted that cerbomed has entrusted us with their trial and look forward to a successful collaboration with the cerbomed team" said Jörg Breitkopf, Managing Director of CPI. "cerbomed's decision to award CPI this important project is a further confirmation of our growing reputation among medical device companies as a highly regarded international CRO for clinical trial support."
About cerbomed GmbH
cerbomed GmbH is currently working on transcutaneous Vagus Nerve Stimulation (t-VNS®), an emerging therapy option for patients with difficult-to-treat neurological and psychiatric illnesses. Its transcutaneous vagus nerve stimulator NEMOS® received the European clearance (CE mark) in 2011. The start of clinical trials to investigate the effectiveness of t-VNS® for the treatment of patients with drug-resistant epilepsy and chronic migraine are planned for early 2012.
